共 17 条
World Association for the Advancement of Veterinary Parasitology (WAAVP): Guideline for the evaluation of drug efficacy against non-coccidial gastrointestinal protozoa in livestock and companion animals
被引:9
作者:
Geurden, T.
[1
,6
]
Olson, M. E.
[2
]
O'Handley, R. M.
[3
]
Schetters, T.
[4
]
Bowman, D.
[5
]
Vercruysse, J.
[1
]
机构:
[1] Univ Ghent, Fac Vet Med, Parasitol Lab, B-9820 Merelbeke, Belgium
[2] Bow Valley Res Inc, Calgary, AB, Canada
[3] Univ Adelaide, Sch Anim & Vet Sci, Roseworthy, SA 5371, Australia
[4] ProtActivity, NL-5432 DD Cuijk, Netherlands
[5] Cornell Univ, Coll Vet Med, Ctr Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA
[6] Zoetis, B-1930 Zaventem, Belgium
关键词:
DAIRY CALVES;
FENBENDAZOLE TREATMENT;
GIARDIA-DUODENALIS;
CYST EXCRETION;
INFECTION;
D O I:
10.1016/j.vetpar.2014.02.050
中图分类号:
R38 [医学寄生虫学];
Q [生物科学];
学科分类号:
07 ;
0710 ;
09 ;
100103 ;
摘要:
The current guideline was written to aid in the design, implementation and interpretation of studies for the assessment of drug efficacy against non-coccidial gastrointestinal protozoan parasites, with Giardia spp. as the leading example. The information provided in this guideline deals with aspects of how to conduct controlled studies using experimental infection models (dose determination and dose confirmation) and efficacy studies in commercial facilities (field effectiveness studies). Furthermore, the selection of suitable animals, housing, infection procedure, choice of diagnostic technique and data analysis are discussed. This guideline is intended to assist investigators in conducting specific studies, to provide specific information for registration authorities involved in the decision-making process, to assist in the approval and registration of new drugs and to facilitate the worldwide adoption of uniform procedures. The primary parameter for drug efficacy is the reduction in either parasite excretion or parasite counts and a minimum efficacy of 90% is required against non-coccidial gastrointestinal protozoa. A supporting efficacy parameter is a significant difference in the proportion of infected animals between treated and non-treated groups. Persistent efficacy is considered as an additional claim to therapeutic efficacy. (C) 2014 Published by Elsevier B.V.
引用
收藏
页码:81 / 86
页数:6
相关论文